As of September 30, 2011, the Company's total cash, cash equivalents and current investment securities were $101.2 million. Net cash used in operating activities was $33.2 million for the first nine months of 2011, while purchases of capital equipment for the same period totaled $13.2 million, funded primarily through utilization of the Company's credit facility.
In October 2011, Sequenom CMM launched its noninvasive proprietary MaterniT21 LDT and began marketing testing services to physicians in 20 major metropolitan regions across the United States. The MaterniT21 LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome.
The MaterniT21 LDT is indicated for use in pregnant women at high-risk for carrying a fetus with Down syndrome and can accurately test maternal blood as early as 10 weeks of gestation. In the United States, there are an estimated 750,000 such high-risk pregnancies each year.
A clinical validation study leading to the introduction of the MaterniT21 LDT was recently published online in the journal Genetics in Medicine. The results of the multi-center study demonstrated high accuracy, detecting nearly all (99.1%) positive cases of fetal trisomy 21 with a very low false positive rate.
"The launch of the MaterniT21 LDT has been the culmination of many years of effort to develop a safer way for clinicians to assess the risk of a fetal abnormality in pre
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved